Health Condition 1: C61- Malignant neoplasm of prostate
Conditions
Interventions
Intervention1: Nil: Nil
Intervention2: Nil: Nil
Intervention3: Nil: Nil
Intervention4: Nil: Nil
Control Intervention1: NIL: NIL
Sponsors
NIL
Eligibility
Inclusion criteria
Inclusion criteria: Patients with histologically confirmed prostate adenocarcinoma. Patients who have undergone Serum PSA testing within 1-3 months prior to imaging or biopsy, MRI with PI-RADS scoring, TRUS-guided biopsy,PET-CT and Radical Prostatectomy with histopathological examination of specimens. Patients with localized or locally advanced disease (cT1 T3). Patients with confirmed distant metastases (e.g., M1 stage). Patients aged 50 80 years with ECOG Performance Status of 0 2. Patients who have not undergone any prior treatment for prostate cancer (e.g., androgen deprivation therapy, chemotherapy, or radiation therapy). Patients who provide written informed consent for participation and data usage in the study.
Exclusion criteria
Exclusion criteria: Patients who have received prior surgical, radiation, or pharmacological treatment for prostate cancer.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Is there a correlation between MRI findings / TRUS Biopsy of prostate + PSMA PET -CT findings in patient with abnormal PSA and finally co relate with Radical prostatectomy specimen?Timepoint: Until complete evaluation at baseline | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate the accuracy of each modality in predicting tumor volume, grade, & stage.Timepoint: Until complete evaluation at baseline;To analyze the concordance of imaging & biopsy with final RP pathology in multifocal vs. unifocal disease.Timepoint: Until complete evaluation at baseline | — |
Countries
India
Contacts
Public ContactDr Patan Saif Khan
Narayana Health
Outcome results
None listed